Anti-PLA2 R IgG (Blood)

Testing Laboratory

Auckland Te Toka Tumai | Auckland Hospital

Department

Immunology

Delphic Registration Code (Alpha Code)

PL2R

Test Code (Numeric Code)

7110

Laboratory Handling

Phlebotomy

Serum, Plasma

Transport

Ambient (8 - 24 °C) within 48 hours; Chilled (4 - 8 °C) if longer than 48 hours

Registration

PL2R

Sample Stability

Up to 48 hours: 8 - 24 °C; Up to 14 days: 4 - 8 °C; Up to 6 months: -30 °C; Indefinite at - 80 °C

Synonyms

anti-phospholipase A2 receptor antibodies
primary membranous nephropathy

Turnaround Time

2 weeks

Specimen Type

• Plasma
• Serum

Specimen Requirements

Tube/Container Type:

Preferred

• SST II (Gold Cap)

Acceptable

• Lithium Heparin - Non-gel (Green Cap)
• Lithium Heparin PST- Gel (Light Green Cap)
• Plain (Red Top)

Preferred Sample Volume (ml)

3.5

Minimum Sample Volume (ml)

1

Paediatric Specimen Requirements

Tube/Container Type:

Preferred

• SST II (Gold Cap)

Acceptable

• Heparin (Microtainer)
• Plain(Microtainer)
• SST(Microtainer)
• Lithium Heparin - Non-gel (Green Cap)
• Lithium Heparin PST- Gel (Light Green Cap)
• Plain (Red Top)

Minimum Sample Volume (ml)

1

Additional Specimen Information

Paediatric Specimen: 2 mL clotted blood or 1 mL serum

Aliquot Instructions

Sample Type

• Serum
• Plasma

Minimum Volume (ml)

0.5

Transport to Lab

Chilled (2 - 8 degrees Celsius)

Test Method

ELISA- automated
DS2 robotic processing

Limitations / Interference

Grossly haemolysed and/or high lipaemic serum specimens.

Uncertainty of Measurement

20%

References

1. Burstein, D.M., S.M. Korbet, and M.M. Schwartz, Membranous glomerulonephritis and malignancy. Am J Kidney Dis, 1993. 22(1): p. 5-10.

2. Beck, L.H., Jr., et al., M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med, 2009. 361(1): p. 11-21.

3. Ronco, P. and H. Debiec, Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol, 2012. 8(4): p. 203-13.

4. Qin, W., et al., Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol, 2011. 22(6): p. 1137-43.

5. Svobodova, B., et al., Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant, 2013. 28(7): p. 1839-44.

6. Debiec, H. and P. Ronco, PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med, 2011. 364(7): p. 689-90.

7. Hofstra, J.M., et al., Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol, 2011. 6(6): p. 1286-91.

8. Michel, P.A., et al., Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra, 2011. 1(1): p. 251-61.

9. Debiec, H., et al., Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant, 2011. 11(10): p. 2144-52.

10. Stahl, R., E. Hoxha, and K. Fechner, PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med, 2010. 363(5): p. 496-8.

Contact Information